To include your compound in the COVID-19 Resource Center, submit it here.

Pertuzumab: Phase III data

The double-blind, international Phase III CLEOPATRA trial in 808 previously untreated HER2-positive breast cancer patients showed that IV pertuzumab every 3 weeks plus

Read the full 235 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE